Prevalence and prognostic value of poor R-wave progression in standard resting electrocardiogram in a general adult population. The Health 2000 Survey

Figures & data

Figure 1. Electrocardiogram of 62-year-old woman with poor R-wave progression (PRWP) without organic heart disease.

Table I. Baseline characteristics of The Health 2000 Survey participants.

	Men					Women
	PRWP– (n = 2393)		PRWP+ (n = 69)			PRWP– (n = 2933)		PRWP+ (n = 218)
	Mean	SD	Mean	SD	P	Mean	SD	Mean	SD	P
Age	50	13	56	15	<0.001	53	15	57	15	<0.001
Height	176	7	173	7	<0.01	162	7	162	6	0.88
Weight	84	14	82	14	0.21	70	14	72	14	0.07
BMI	27.1	4.1	27.2	4.2	0.84	26.8	5.0	27.5	5.3	0.05
fS-Gluk (mmol/L)	5.7	1.3	5.9	2.1	0.14	5.4	1.1	5.6	1.4	0.02
fS-Chol (mmol/L)	6.0	1.1	5.9	1.0	0.40	5.9	1.1	6.0	1.1	0.28
fS-Chol-HDL (mmol/L)	1.2	0.3	1.2	0.4	0.30	1.4	0.4	1.4	0.4	0.83
fS-Chol-LDL (mmol/L)	3.9	1.0	3.7	1.0	0.13	3.6	1.0	3.7	1.1	0.47
fS-Trigly (mmol/L)	1.8	1.2	2.0	1.5	0.22	1.4	0.7	1.5	0.7	0.37

PRWP–= no poor R-wave progression; PRWP+ = poor R-wave progression; SD = standard deviation; BMI = body mass index;

fS-Gluk = fasting serum glucose; fS-Chol = fasting serum cholesterol; fS-Chol-HDL = fasting serum high-density lipoprotein cholesterol;

fS-Chol-LDL = fasting serum low-density lipoprotein cholesterol; fS-Trigly = fasting serum triglyceride.

Figure 2. Prevalence of poor R-wave progression for the three age groups among men (black bars) and women (white bars); the upper 95% confidence interval limits and the significances of the difference between the sexes are shown (chi-square test).

Table II. Clinical characteristics and mortality of the study population.

	Men			Women
	PRWP–	PRWP +		PRWP–	PRWP+
	n (%)	n (%)	P	n (%)	n (%)	P
Regular smoking	658 (27.6)	25 (36.2)	0.13	490 (16.8)	41 (18.9)	0.45
COPD	35 (1.5)	2 (2.9)	0.28	33 (1.1)	4 (1.8)	0.32
Hypertension	713 (29.9)	23 (33.3)	0.59	851 (29.1)	88 (40.6)	<0.01
Diabetes	122 (5.1)	8 (11.6)	0.03	141 (4.8)	25 (11.5)	<0.001
LVH/RVH	503 (21.1)	11 (15.9)	0.07	284 (9.7)	22 (10.1)	0.16
CHD
No	2159 (90.2)	52 (75.4)		2652 (90.4)	188 (86.2)
Possible	35 (1.5)	0 (0)	<0.001	72 (2.5)	6 (2.8)	0.10
Yes	199 (8.3)	17 (24.6)		209 (7.1)	24 (11.0)
MI
No	2304 (96.3)	60 (87)		2876 (98.1)	207 (95)
Possible	18 (0.8)	2 (2.9)	<0.001	12 (0.4)	3 (1.4)	<0.01
Yes	71 (3)	7 (10.1)		45 (1.5)	8 (3.7)
Death, all-cause	149 (6.2)	10 (14.5)	0.01	135 (4.6)	23 (10.6)	<0.01
Death, cardiovascular	60 (2.5)	5 (7.2)	0.03	44 (1.5)	11 (5)	<0.01
Medication
Beta-blocker	258 (10.8)	16 (23.2)	<0.01	426 (14.5)	46 (21.1)	0.01
Ccb	121 (5.1)	4 (5.8)	0.78	177 (6.0)	19 (8.7)	0.14
ACI/ARB	188 (7.9)	8 (11.6)	0.26	227 (7.7)	20 (9.2)	0.43

Follow-up of 70 ± 9 months (mean ± SD).

PRWP = no poor R-wave progression; PRWP+ = poor R-wave progression; COPD = chronic obstructive pulmonary disease;

LVH = left ventricular hypertrophy; RVH = right ventricular hypertrophy; CHD = coronary heart disease; MI = myocardial infarction;

Ccb = calcium channel blocker; ACI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor antagonist.